CVS Health schedules November 4 results. CVS Health stock sits 16.39 percent below its 52-week high
Published on 10/27/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming results and earnings recovery
- CVS Health scheduled its third-quarter results call for November 4, 2026.
- Second-quarter revenue rose 7.30 percent year over year to USD 106.10 billion.
- CVS Health stock trades at EUR 83.22 at 10:37 a.m. CET at Lang & Schwarz on October 27, 2026, 0.51 percent above the Xetra close of October 26, 2026.
- JPMorgan Chase raised its target from USD 111.00 to USD 118.00 on August 12, 2026.
CVS Health Corp. (ISIN US1266501006) is trading at EUR 83.22 at Lang & Schwarz on October 27, 2026 at 10:37 a.m. CET, 0.51 percent above the Xetra close of October 26, 2026 at EUR 82.80. The company will discuss third-quarter 2026 results on November 4, 2026, giving investors a firm date for the next test of its earnings recovery.
November 4 sets the next test
According to CVS Health on October 5, 2026, the company scheduled its third-quarter earnings conference call for November 4 at 8:00 a.m. ET. The appointment follows second-quarter revenue of USD 106.10 billion and diluted earnings per share of USD 2.58, according to MarketBeat on October 19, 2026.
What does the earnings recovery mean?
The latest quarter showed a quantified improvement: revenue increased 7.30 percent from the year-earlier period, while earnings per share reached USD 2.58 versus USD 1.87 expected, MarketBeat reported on October 19, 2026. The result gives the November report a demanding comparison base, especially as the company has raised its full-year 2026 earnings guidance.
The chronology is clear. On May 6, 2026, CVS Health reported first-quarter revenue of USD 100.40 billion and raised its full-year guidance, according to TickerScout. On August 5, 2026, second-quarter revenue reached USD 106.10 billion and diluted earnings per share were USD 2.58, according to MarketBeat. On October 5, 2026, CVS Health scheduled the November 4 earnings call.
Analysts set a higher bar
JPMorgan Chase raised its CVS Health price target from USD 111.00 to USD 118.00 on August 12, 2026, while keeping an overweight rating, according to MarketBeat. The counter-factor is cost pressure in managed care, which could make the third-quarter margin and guidance discussion more important than revenue growth alone.
CVS Health stock stays near its annual range
CVS Health stock was trading at EUR 83.22 at Lang & Schwarz on October 27, 2026 at 10:37 a.m. CET, 0.51 percent above the Xetra close of October 26, 2026 at EUR 82.80. The primary listing is on the NYSE, where CVS Health was last quoted at USD 92.53 on October 26, 2026 at 4:00 p.m. ET.
The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.
CVS Health stock facts
- Company: CVS Health Corp.
- ISIN: US1266501006
- Ticker: CVS
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 27, 2026, 10:37 a.m. CET): EUR 83.22
- Change versus Xetra close: plus 0.51 percent
- Xetra close (October 26, 2026): EUR 82.80
- Market capitalization: EUR 106.9 billion (as of October 27, 2026)
- 52-week range: EUR 59.71-96.90 (as of October 27, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
